Please login to the form below

Not currently logged in
Email:
Password:

Pfizer generic on hold until 2019

A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019
A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019.

Israel-based Teva had claimed Pfizer's patent on Viagra (sildenafil) wasn't valid and couldn't be enforced. It also claimed that Pfizer intentionally withheld documents from the US Patent and Trademark Office.

But US Judge Rebecca Smith, Virginia said that Teva had presented no clear and convincing evidence to support this, in a 110-page opinion.

The decision was made at the end of a two-week non-jury trial. It protects Pfizer's $1bn a year in US Viagra sales.

Pfizer has noted that the decision is subject to appeal. Litigation on the same patent against other companies remains pending.

16th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics